5444-61-1

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is used as a potential anti-cancer agent for its selective cytotoxicity towards cancer cells, which makes it a candidate for developing targeted cancer therapies. This selective action could potentially minimize damage to healthy cells, thereby reducing side effects commonly associated with traditional chemotherapy.
Used in Anti-inflammatory Applications:
BzPP is utilized in the research and development of anti-inflammatory drugs due to its potential to modulate inflammatory responses. This application could be beneficial in treating a variety of conditions where inflammation is a key factor, such as autoimmune diseases and chronic inflammatory disorders.
Used in Anti-microbial Applications:
In the field of infectious diseases, 1-Benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is explored as an anti-microbial agent, indicating its potential to combat bacterial and other microbial infections. This could be particularly relevant in the context of increasing antibiotic resistance and the need for new antimicrobial agents.
Overall, 1-Benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is a multifaceted compound with applications spanning across various areas of medicine, from oncology to infectious disease management. Its development and application in these fields could lead to significant advancements in treatment options and patient outcomes.

InChI:InChI=1/C12H11N5/c13-11-10-6-16-17(12(10)15-8-14-11)7-9-4-2-1-3-5-9/h1-6,8H,7H2,(H2,13,14,15)

Upstream product

• 555-96-4 Benzylhydrazine 
• 100-39-0 benzyl bromide 
• 2380-63-4 4-Aminopyrazolo<3,4-d>pyrimidin 
• 91091-13-3 5-amino-1-benzyl-1H-pyrazole-4-carbonitrile 
• 77287-34-4 formamide 

Relevant academic research and scientific papers

Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies

This study reports the synthesis of a number of 1- and 2-alkyl derivatives of the 4-aminopyrazolo[3,4-d]pyrimidine (APP) nucleus and their evaluation as inhibitors of ADA from bovine spleen. The 2-substituted aminopyrazolopyrimidines proved to be potent inhibitors, most of them exhibiting Ki values in the nanomolar/subnanomolar range. In this series the inhibitory activity is enhanced with the increase in length of the alkyl chain, reaching a maximum with the n-decyl substituent. Insertion of a 2′-hydroxy group in the ra-decyl chain gave 3k, whose (R)-isomer displayed the highest inhibitory potency of the series (Ki 0.053 nM), showing an activity 2 orders of magnitude higher than that of (+)-EHNA (Ki 1.14 nM), which was taken as the reference standard. Docking simulations of aminopyrazolopyrimidines into the ADA binding site were also performed, to rationalize the structure-activity relationships of this class of inhibitors.

Synthesis and anticonvulsant activity of N-benzylpyrrolo[2,3-d]-, - pyrazolo[3,4-d]-, and -triazolo[4,5-d]pyrimidines: Imidazole ring-modified analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine

Analogues of 9-(2-fluorobenzyl)-6-(methylamino)-9H-purine (1) containing isosteric replacements of the imidazole ring atoms were synthesized and tested for anticonvulsant activity. The pyrrolo[2,3-d]-, pyrazolo[a,4-d]-, and triazolo[4,5-d]pyrimidines were less active than 1 against maximal electroshock-induced seizures (MES) in rats when given po. The differences in anti-MES activity for these analogues was not explained by differences in pK(a) or lipophilicity. However, the four classes of heterocycles have distinctly different calculated electrostatic isopotential maps, which may be related to optimum anticonvulsant activity.